FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114889596> ?p ?o ?g. }

• W2114889596 endingPage "242" @default.
• W2114889596 startingPage "237" @default.
• W2114889596 abstract "Abstract Background: Levofloxacin has been proposed as an alternative to classic therapy in secondary resistance to Helicobacter pylori . Aim: To evaluate primary and secondary resistance of H. pylori to levofloxacin, and to test the role of susceptibility test on the efficacy of levofloxacin‐based triple therapy. Methods: Eighty consecutive dyspeptic patients with positive 13 C‐urea breath test never treated were randomly allocated into group A 1 (40 patients) and group B 1 (39 patients). Eighty‐three patients already treated unsuccessfully with positive 13 C‐urea breath test were divided into group A 2 (51 patients) and group B 2 (32 patients). Patients in group A 1 and group A 2 underwent upper gastrointestinal endoscopy for H. pylori susceptibility test to amoxicillin, clarithromycin, tinidazole, rifabutin, and levofloxacin. These patients were treated with levofloxacin (500 mg b.i.d.), amoxicillin (1 g b.i.d.) and esomeprazole (20 mg b.i.d.) for 10 days if sensitive to these two antibiotics. If H. pylori was found resistant to amoxicillin and/or levofloxacin the treatment was based on the indications of the susceptibility test. Patients in group B 1 and group B 2 were treated empirically with levofloxacin, amoxicillin, and esomeprazole at the same dose and duration as group A. All patients underwent 13 C‐urea breath test 2 months after the end of therapy. Results: The antibiotic resistance of H. pylori strains in group A 1 and group A 2 was (%): amoxicillin: 2.4, 10; clarithromycin: 21.9, 43.1; tinidazole: 31.7, 70; rifabutin: 2.4, 4; and levofloxacin: 9.7, 12.2, respectively. In group A 1 with susceptibility test‐driven therapy, eradication was 97.2%, and in group B 1 with empirical treatment, 94.1% (n.s.). In group A 2 with susceptibility test, eradication was 97.5%, whereas in group B 2 with empirical treatment 81.2% ( p < .01). Conclusion: Primary and secondary resistance of H. pylori to levofloxacin is approximately 10% of the tested strains. The susceptibility test does not influence therapeutic outcome of triple therapy with amoxicillin and levofloxacin in patients never treated, while it is determinant for patients who were previously treated without success." @default.
• W2114889596 created "2016-06-24" @default.
• W2114889596 creator A5003775828 @default.
• W2114889596 creator A5007461560 @default.
• W2114889596 creator A5013568515 @default.
• W2114889596 creator A5048401764 @default.
• W2114889596 creator A5080589186 @default.
• W2114889596 date "2006-07-13" @default.
• W2114889596 modified "2023-10-16" @default.
• W2114889596 title "Role of the Preliminary Susceptibility Testing for Initial and After Failed Therapy of <i>Helicobacter pylori</i> Infection with Levofloxacin, Amoxicillin, and Esomeprazole" @default.
• W2114889596 cites W1797829304 @default.
• W2114889596 cites W1970040819 @default.
• W2114889596 cites W1984316482 @default.
• W2114889596 cites W1995346848 @default.
• W2114889596 cites W2022747373 @default.
• W2114889596 cites W2028154233 @default.
• W2114889596 cites W2033155004 @default.
• W2114889596 cites W2042913461 @default.
• W2114889596 cites W2049656709 @default.
• W2114889596 cites W2053868156 @default.
• W2114889596 cites W2056695902 @default.
• W2114889596 cites W2058555112 @default.
• W2114889596 cites W2060857171 @default.
• W2114889596 cites W2062835498 @default.
• W2114889596 cites W2067126845 @default.
• W2114889596 cites W2073558647 @default.
• W2114889596 cites W2078931704 @default.
• W2114889596 cites W2106683700 @default.
• W2114889596 cites W2107740419 @default.
• W2114889596 cites W2108165724 @default.
• W2114889596 cites W2108185286 @default.
• W2114889596 cites W2134155826 @default.
• W2114889596 cites W2159156126 @default.
• W2114889596 cites W2427501075 @default.
• W2114889596 cites W4237403611 @default.
• W2114889596 doi "https://doi.org/10.1111/j.1523-5378.2006.00407.x" @default.
• W2114889596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16882326" @default.
• W2114889596 hasPublicationYear "2006" @default.
• W2114889596 type Work @default.
• W2114889596 sameAs 2114889596 @default.
• W2114889596 citedByCount "63" @default.
• W2114889596 countsByYear W21148895962012 @default.
• W2114889596 countsByYear W21148895962013 @default.
• W2114889596 countsByYear W21148895962014 @default.
• W2114889596 countsByYear W21148895962015 @default.
• W2114889596 countsByYear W21148895962016 @default.
• W2114889596 countsByYear W21148895962017 @default.
• W2114889596 countsByYear W21148895962020 @default.
• W2114889596 countsByYear W21148895962021 @default.
• W2114889596 countsByYear W21148895962022 @default.
• W2114889596 countsByYear W21148895962023 @default.
• W2114889596 crossrefType "journal-article" @default.
• W2114889596 hasAuthorship W2114889596A5003775828 @default.
• W2114889596 hasAuthorship W2114889596A5007461560 @default.
• W2114889596 hasAuthorship W2114889596A5013568515 @default.
• W2114889596 hasAuthorship W2114889596A5048401764 @default.
• W2114889596 hasAuthorship W2114889596A5080589186 @default.
• W2114889596 hasConcept C126322002 @default.
• W2114889596 hasConcept C2775981797 @default.
• W2114889596 hasConcept C2776409635 @default.
• W2114889596 hasConcept C2776962512 @default.
• W2114889596 hasConcept C2777172195 @default.
• W2114889596 hasConcept C2777396551 @default.
• W2114889596 hasConcept C2777785397 @default.
• W2114889596 hasConcept C2778204628 @default.
• W2114889596 hasConcept C2779708577 @default.
• W2114889596 hasConcept C2780626017 @default.
• W2114889596 hasConcept C2780867798 @default.
• W2114889596 hasConcept C2781276175 @default.
• W2114889596 hasConcept C2908868296 @default.
• W2114889596 hasConcept C501593827 @default.
• W2114889596 hasConcept C71924100 @default.
• W2114889596 hasConcept C86803240 @default.
• W2114889596 hasConcept C89423630 @default.
• W2114889596 hasConcept C90924648 @default.
• W2114889596 hasConceptScore W2114889596C126322002 @default.
• W2114889596 hasConceptScore W2114889596C2775981797 @default.
• W2114889596 hasConceptScore W2114889596C2776409635 @default.
• W2114889596 hasConceptScore W2114889596C2776962512 @default.
• W2114889596 hasConceptScore W2114889596C2777172195 @default.
• W2114889596 hasConceptScore W2114889596C2777396551 @default.
• W2114889596 hasConceptScore W2114889596C2777785397 @default.
• W2114889596 hasConceptScore W2114889596C2778204628 @default.
• W2114889596 hasConceptScore W2114889596C2779708577 @default.
• W2114889596 hasConceptScore W2114889596C2780626017 @default.
• W2114889596 hasConceptScore W2114889596C2780867798 @default.
• W2114889596 hasConceptScore W2114889596C2781276175 @default.
• W2114889596 hasConceptScore W2114889596C2908868296 @default.
• W2114889596 hasConceptScore W2114889596C501593827 @default.
• W2114889596 hasConceptScore W2114889596C71924100 @default.
• W2114889596 hasConceptScore W2114889596C86803240 @default.
• W2114889596 hasConceptScore W2114889596C89423630 @default.
• W2114889596 hasConceptScore W2114889596C90924648 @default.
• W2114889596 hasIssue "4" @default.
• W2114889596 hasLocation W21148895961 @default.
• W2114889596 hasLocation W21148895962 @default.
• W2114889596 hasOpenAccess W2114889596 @default.
• W2114889596 hasPrimaryLocation W21148895961 @default.

• next